Literature DB >> 9793794

Increase in histamine production by inflammatory exudate in the chronic phase of allergic inflammation in rats.

N Hirasawa1, M Shiraishi, S Oikawa, S Mue, K Ohuchi.   

Abstract

In the air pouch-type allergic inflammation in rats, we reported that a sustained histamine production in the late phase is induced by a cytokine-like factor, named histamine-production-increasing factor (HPIF) (1). Recently, we found another type of histamine-production-increasing factor in the pouch fluid at the chronic phase of air pouch-type allergic inflammation. Although it did not increase histamine production by itself, it enhanced the HPIF-induced histamine production by rat bone marrow cells. It also increased GM-CSF-induced histamine production. The activity of this factor increased time-dependently from 3 to 7 days after the antigen challenge. Injection of the 5 day pouch fluid sample containing this factor into the pouch 4 h after the antigen challenge increased histamine contents in the pouch fluid at 24 h, indicating that this factor enhances HPIF-induced histamine production in vivo. Biochemical analysis of the 5 day pouch fluid sample indicated that this factor is a heat-labile and trypsin-sensitive protein of which pI value and molecular weight are 7-8 and about 100 kDa, respectively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9793794     DOI: 10.1023/a:1022393926234

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  19 in total

Review 1.  Signal transduction by Fc receptors: the Fc epsilon RI case.

Authors:  M A Beaven; H Metzger
Journal:  Immunol Today       Date:  1993-05

2.  Skin allografts generate an enhanced production of histamine and histamine-producing cell-stimulating factor (HCSF) by spleen cells in response to T cell mitogens.

Authors:  M Dy; B Lebel
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

3.  Increase in histidine decarboxylase activity in mouse skin after application of the tumor promoter tetradecanoylphorbol acetate.

Authors:  T Watanabe; Y Taguchi; K Sasaki; K Tsuyama; Y Kitamura
Journal:  Biochem Biophys Res Commun       Date:  1981-05-15       Impact factor: 3.575

4.  Occurrence of histamine-production-increasing factor in the postanaphylactic phase of allergic inflammation.

Authors:  N Hirasawa; K Ohuchi; K Kawarasaki; M Watanabe; S Tsurufuji
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

5.  Simultaneous induction of histidine and ornithine decarboxylases and changes in their product amines following the injection of Escherichia coli lipopolysaccharide into mice.

Authors:  Y Endo
Journal:  Biochem Pharmacol       Date:  1982-04-15       Impact factor: 5.858

Review 6.  Active translocation of platelets into sinusoidal and Disse spaces in the liver in response to lipopolysaccharides, interleukin-1 and tumor necrosis factor.

Authors:  Y Endo; M Nakamura
Journal:  Gen Pharmacol       Date:  1993-09

7.  GM-CSF and G-CSF stimulate the synthesis of histamine and putrescine in the hematopoietic organs in vivo.

Authors:  Y Endo; T Kikuchi; Y Takeda; Y Nitta; H Rikiishi; K Kumagai
Journal:  Immunol Lett       Date:  1992-06       Impact factor: 3.685

8.  Mechanism of the inhibitory action of cyclooxygenase inhibitors on leukocyte infiltration: involvement of endogenous histamine.

Authors:  N Hirasawa; K Ohuchi; M Watanabe; S Tsurufuji
Journal:  Eur J Pharmacol       Date:  1987-12-15       Impact factor: 4.432

9.  Interleukin 1 and/or tumor necrosis factor-alpha synergize with granulocyte-macrophage colony-stimulating factor to enhance histamine synthesis in hematopoietic cells: role of prostaglandin E2.

Authors:  C Piquet-Pellorce; F Homo-Delarche; M Dy
Journal:  Eur J Immunol       Date:  1989-11       Impact factor: 5.532

10.  Pharmacological analysis of the vascular permeability response in the anaphylactic phase of allergic inflammation in rats.

Authors:  K Ohuchi; N Hirasawa; M Watanabe; S Tsurufuji
Journal:  Eur J Pharmacol       Date:  1985-11-19       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.